Serotonin syndrome associated with MDPV use: A case report

Annals of Emergency Medicine

Volumn 60, Issue 1, 2012, Pages 100-102

  Mugele, Josh ^a   Nañagas, Kristine A ^a   Tormoehlen, Laura M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; AMPHETAMINE; BATH SALT; BENZODIAZEPINE; CYPROHEPTADINE; DIAZEPAM; FENTANYL; LORAZEPAM; MIDAZOLAM; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AERATION; AGITATION; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BATH; CASE REPORT; DISEASE COURSE; DRUG INFUSION; DRUG STRUCTURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEMALE; HALLUCINATION; HOSPITALIZATION; HUMAN; HYGIENE PRODUCT; INGESTION; INTENSIVE CARE UNIT; PNEUMOTHORAX; PRIORITY JOURNAL; SEDATION; SEROTONIN SYNDROME; THORAX DRAINAGE;

ADULT; BENZODIOXOLES; DESIGNER DRUGS; FEMALE; HUMANS; PYRROLIDINES; SEROTONIN SYNDROME;

EID: 84860488943     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2011.11.033     Document Type: Article

References (15)

1. Drug and Chemical Evaluation Section. DEA report: methylenedioxypyrovalerone (MDPV). Available at: http://www.deadiversion.usdoj. gov/drugs-concern/mdpv.pdf. Accessed June 15, 2011.
2. Benzie F, Hekman K, Wade DR, et al. Emergency department visits after use of a drug sold as "bath salts" - Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60:624-627.
3. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635-642.
4. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
5. Parrott AC. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav. 2002;71:837-844.
6. Wood DM, Davies S, Greene SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila). 2010;48:924-927.
7. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559:132-137.
8. Fleckenstein AE, Haughey HM, Metzger RR, et al. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol. 1999;382:45-49.
9. Schifano F, Albanese A, Fergus S, et al. Mephedrone (4- methylmethcathinone; "meow meow"): chemical, pharmacological and clinical issues. Psychopharmacology. 2011;214:593-602.
10. Gillman PK. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust. 1997;167:109-111.
11. Roy S, Fortier L-P. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine. Can J Anaesth. 2003;50:32-35.
12. Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth. 2008;55:521-525.
13. Ailawadhi S, Sung KW, Carlson LA, et al. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther. 2007;32:199-202.
14. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity [review]. Br J Anaesth. 2005;95:434-441.
15. Tao R, Karnik M, Ma Z, et al. Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors. Br J Pharmacol. 2003;139:1498-1504.